The "Alzheimer's disease signature": Potential perspectives for novel biomarkers

Immunity and Ageing

Volumn 8, Issue , 2011, Pages

  Davinelli, Sergio ^a   Intrieri, Mariano ^a   Russo, Claudio ^a   Di Costanzo, Alfonso ^a   Zella, Davide ^b   Bosco, Paolo ^c   Scapagnini, Giovanni ^a  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BETA SECRETASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CHROMOGRANIN A; CLATHRIN ASSEMBLY PROTEIN; CLUSTERIN; COMPLEMENT FACTOR H; CYCLIN DEPENDENT KINASE 5; EPHRIN RECEPTOR A1; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROMODULIN; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; SORTILIN; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VISININ;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID; DNA MICROARRAY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

EID: 80053172278     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-8-7     Document Type: Review

References (94)

1. Alzheimer's Association 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6:158-94. Alzheimer's Association.
2. Ho L, Fivecoat H, Wang J, Pasinetti GM. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol 2010, 45:15-22. 10.1016/j.exger.2009.09.007, 2840994, 19796674.
3. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002, 359:881-4. 10.1016/S0140-6736(02)07948-5, 11897304.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010, 362:329-44. 10.1056/NEJMra0909142, 20107219.
5. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 2009, 32:150-9. 10.1016/j.tins.2008.11.007, 19162340.
6. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185. 10.1126/science.1566067, 1566067.
7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403. 10.1016/S0140-6736(06)69113-7, 16876668.
8. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008, 65:1102-1107. 10.1001/archneur.65.8.1102, 18695061.
9. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007, 64:718-726. 10.1001/archpsyc.64.6.718, 17548753.
10. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010, 56:484-546. 10.1016/j.disamonth.2010.06.001, 2941917, 20831921.
11. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009, 41:1261-68. 10.1016/j.biocel.2008.12.015, 2680505, 19124085.
12. Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol 2010, 45:23-9. 10.1016/j.exger.2009.08.002, 19698775.
13. Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR, et al. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004, 4:2234-2241. 10.1002/pmic.200300822, 15274117.
14. Finehout EJ, Franck Z, Relkin N, Lee KH. Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem 2006, 52:1906-1913. 10.1373/clinchem.2006.070508, 16887899.
15. Hernandez F, Avila J. Tauopathies. Cell Mol Life Sci 2007, 64:2219-2233. 10.1007/s00018-007-7220-x, 17604998.
16. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007, 282:23645-23654. 10.1074/jbc.M703269200, 17562708.
17. Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 2010, 112:1353-67. 10.1111/j.1471-4159.2009.06511.x, 19943854.
18. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-42. 10.1016/j.neuron.2008.11.007, 2692134, 19038212.
19. Takashima A. Amyloid-beta, tau, and dementia. J Alzheimers Dis 2009, 17:729-36.
20. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009, 110:1129-1134. 10.1111/j.1471-4159.2009.06181.x, 19457065.
21. Devi L, Anandatheerthavarada HK. Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 2010, 1802:11-19. 2790550, 19619643.
22. Mancuso C, Scapagnini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007, 12:1107-1123. 10.2741/2130, 17127365.
23. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63:168-174. 10.1001/archpsyc.63.2.168, 16461860.
24. Wegiel J, Gong CX, Hwang YW. The role of DYRK1A in neurodegenerative diseases. FEBS J 2011, 278:236-45. 10.1111/j.1742-4658.2010.07955.x, 21156028.
25. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007, 16:15-23.
26. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995, 92:4725-4727. 10.1073/pnas.92.11.4725, 41779, 7761390.
27. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923. 10.1126/science.8346443, 8346443.
28. Wolk DA, Dickerson BC, . Alzheimer's Disease Neuroimaging Initiative Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer disease. Proc Natl Acad Sci USA 2010, 107:10256-10261. 10.1073/pnas.1001412107, 2890481, 20479234, Alzheimer's Disease Neuroimaging Initiative.
29. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genet 2009, 41:1088-93. 10.1038/ng.440, 2845877, 19734902.
30. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2002, 99:10843-10848. 10.1073/pnas.162228299, 125060, 12145324.
31. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW. ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41:193-202. 10.1016/S0896-6273(03)00850-X, 14741101.
32. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999, 10:2687-2702. 25500, 10436022.
33. Harel A, Wu F, Mattson MP, Morris CM, Yao PJ. Evidence for CALM in directing VAMP2 trafficking. Traffic 2008, 9:417-429. 10.1111/j.1600-0854.2007.00694.x, 18182011.
34. Yao PJ, Petralia RS, Bushlin I, Wang Y, Furukawa K. Synaptic distribution of the endocytic accessory proteins AP180 and CALM. J Comp Neurol 2005, 481:58-69. 10.1002/cne.20362, 15558718.
35. Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, Gagliani MC, et al. Amyloid precursor protein and Presenilin1 interact with the adaptor GRB2 and modulate ERK 1,2 signaling. J Biol Chem 2007, 282:13833-13844. 10.1074/jbc.M610146200, 17314098.
36. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54:713-720. 10.1016/j.neuron.2007.05.022, 2587162, 17553421.
37. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 2010, 19:3295-3301. 10.1093/hmg/ddq221, 2908469, 20534741.
38. Khera R, Das N. Complement Receptor 1: Disease associations and therapeutic implications. Mol Immunol 2009, 46:761-772. 10.1016/j.molimm.2008.09.026, 19004497.
39. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840. 10.1001/jama.2010.574, 2989531, 20460622.
40. Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol 2009, 11:1399-1410. 10.1038/ncb1986, 2788952, 19915558.
41. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol 2010, 67:961-964. 10.1001/archneurol.2010.147, 2919638, 20554627.
42. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43:429-35. 10.1038/ng.803, 21460840.
43. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011, 43:436-41. 10.1038/ng.801, 21460841.
44. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000, 55:480-483.
45. Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D, et al. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch Gen Psychiatry 2011, 68:198-206. 10.1001/archgenpsychiatry.2010.194, 21300947.
46. Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN, et al. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol 2011, 69:47-64. 10.1002/ana.22308, 21280075.
47. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79. 10.1212/WNL.0b013e318204a397, 21123754.
48. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammà C, et al. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 2009, 61:60-68. 10.1016/j.brainresrev.2009.05.001, 19445962.
49. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413. 10.1002/ana.21610, 2696350, 19296504.
50. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362. 10.1038/nm1653, 17934472.
51. Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One 2009, 4:e4183. 10.1371/journal.pone.0004183, 2613557, 19159013.
52. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-69. 10.1074/mcp.M400129-MCP200, 15385600.
53. Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003, 75:1895-904. 10.1021/ac0262560, 12713048.
54. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999. 10.1038/13690, 10504701.
55. Schmidt A, Kellermann J, Lottspeich F. novel strategy for quantitative proteomics using isotope-coded protein labels. A Proteomics 2005, 5:4-15.
56. Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS, et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008, 39:1186-97. 10.1016/j.neuroimage.2007.09.073, 2390889, 18054253.
57. Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 2008, 43:458-69. 10.1016/j.neuroimage.2008.07.013, 18691658.
58. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010, 8:89. 10.1186/1741-7015-8-89, 3022870, 21176189.
59. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Journal of Neural Transmission 2009, 116:203-12. 10.1007/s00702-008-0177-6, 19142572.
60. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010, 119:669-78. 10.1007/s00401-010-0667-0, 2880811, 20232070.
61. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010, 6:230-238. 10.1016/j.jalz.2010.03.008, 2867838, 20451871.
62. Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med 2009, 3:735-737. 10.2217/bmm.09.65, 20477711.
63. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging 2011, 32:1090-1098. 10.1016/j.neurobiolaging.2009.06.002, 19604603.
64. Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, et al. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener Dis 2008, 5:268-76. 10.1159/000119457, 18309230.
65. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 2008, 54:1617-23. 10.1373/clinchem.2008.104497, 2672199, 18703769.
66. Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001, 12:257-64. 10.1159/000051268, 11351137.
67. Hesse C, Nilsson CL, Blennow K, Davidsson P. Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2001, 22:1834-1837. 10.1002/1522-2683(200105)22:9<1834::AID-ELPS1834>3.0.CO;2-V, 11425239.
68. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13:611-615. 10.1097/00001756-200204160-00015, 11973456.
69. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003, 118:140-146.
70. Korolainen MA, Nyman TA, Nyyssönen P, Hartikainen ES, Pirttilä T. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem 2007, 53:657-65. 10.1373/clinchem.2006.078014, 17289803.
71. Sihlbom C, Davidsson P, Sjögren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res 2008, 33:1332-40. 10.1007/s11064-008-9588-x, 18288611.
72. Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A. Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand 2008, 118:1-11.
73. Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, et al. Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis 2008, 15:409-17. 2667787, 18997294.
74. Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci 2007, 33:114-119. 10.1007/s12031-007-0044-1, 17901555.
75. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic Biol Med 2010, 48:136-144. 10.1016/j.freeradbiomed.2009.10.035, 2818480, 19854267.
76. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999, 19:223-230. 10.1023/A:1020568013953, 10471976.
77. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006, 21:9-15. 10.1159/000089137, 16244482.
78. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 2006, 63:538-43. 10.1001/archneur.63.4.538, 16606766.
79. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 2003, 60:1218-1222. 10.1001/archneur.60.9.1218, 12975286.
80. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci 2006, 27:33-39. 10.1007/s10072-006-0562-6, 16688597.
81. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6:e16032. 10.1371/journal.pone.0016032, 3020224, 21264269.
82. De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV. Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids 2010, 82:57-60. 10.1016/j.plefa.2009.07.006, 19726172.
83. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999, 257:787-91. 10.1006/bbrc.1999.0552, 10208861.
84. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002, 23(4):485-508. 10.1016/S0197-4580(01)00328-1, 12009495.
85. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68:1902-8. 10.1212/01.wnl.0000263217.36439.da, 17536046.
86. Teunissen CE, Scheltens P. Use of proteomic approaches to identify disease biomarkers. Lancet Neurol 2007, 6(12):1036-7. 10.1016/S1474-4422(07)70276-4, 18031700.
87. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 2004, 62:1869-71.
88. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008, 16:343-54.
89. Hochstrasser T, Weiss E, Marksteiner J, Humpel C. Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010, 45:70-74. 10.1016/j.exger.2009.10.005, 19836440.
90. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 2010, 45:75-79. 10.1016/j.exger.2009.09.005, 2815204, 19782124.
91. Sun MK, Hongpaisan J, Alkon DL. Postischemic PKC activation rescues retrograde and anterograde long-term memory. Proc Natl Acad Sci USA 2009, 106:14676-80. 10.1073/pnas.0907842106, 2732881, 19667190.
92. de Barry J, Liégeois CM, Janoshazi A. Protein kinase C as a peripheral biomarker for Alzheimer's disease. Exp Gerontol 2010, 45:64-69. 10.1016/j.exger.2009.10.015, 19895879.
93. Isagawa T, Mukai H, Oishi K, Taniguchi T, Hasegawa H, Kawamata T, et al. Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochem Biophys Res Commun 2000, 273:209-12. 10.1006/bbrc.2000.2926, 10873588.
94. Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T. An update on clinical proteomics in Alzheimer's research. J Neurochem 2010, 112:1386-414. 10.1111/j.1471-4159.2009.06558.x, 20050976.